Protavio is pleased to share our active participation in the 4th consortium meeting of the DIOPTRA project, held in Riga, Latvia, on October 29th and 30th. Funded by Horizon Europe, the consortium brings together industry leaders, research institutions and clinical sites committed to advancing healthcare innovation. This two-day event was a hub of productive discussions, collaborative brainstorming, and a renewed commitment to DIOPTRA’s mission of transforming colorectal cancer (CRC) screening through innovative solutions.
The DIOPTRA EU Mission Cancer project aims to discover novel biomarkers and ultimately develop an innovative diagnostic tool for the early detection of CRC, which remains one of the most common and deadly cancers worldwide. By leveraging advanced affinity proteomics technologies from both the Olink and Luminex platforms, the project seeks to facilitate earlier diagnosis, improve patient outcomes, and reduce healthcare costs associated with late-stage detection.
Protavio presented its recent work on mechanism-based biomarker discovery and the development of the multiplex biomarker panel for CRC profiling, highlighting how our solutions are contributing to the overall objectives of the DIOPTRA project.
Significant progress was made during the meeting, particularly in the rapid development of the project’s mobile application. With the backend and content management system now completed, we are one step closer to providing a user-friendly platform for personalized risk estimation through non-invasive liquid biopsies.
We are excited about the next phases of the DIOPTRA project and remain dedicated to contributing to its success. The insights gained and decisions made during the plenary meeting will guide our efforts as we work towards achieving our shared objectives.